CRI: “Immunotherapy prior to surgery could well become a game-changer” – Mark Saunders
Cancer Research Institute (CRI) shared on LinkedIn: .
“According to clinical trial results presented at ASCO24, giving the immunotherapy drug pembrolizumab before surgery instead of chemotherapy resulted in a significant increase in patients with stage two or stage three MMR deficient/MSI-High bowel cancer being declared cancer-free following surgery.
‘Immunotherapy prior to surgery could well become a ‘game-changer’ for these patients,’ describes Dr. Mark Saunders, a Consultant Clinical Oncologist at The Christie NHS Foundation Trust.
Read more about these findings from UCL, University College London Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, University Hospital Southampton NHS FT, and University of Glasgow investigators.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023